ST香雪：TAEST16001用于治疗晚期食管癌、晚期非小细胞肺癌，暂未开展临床试验

Core Viewpoint - The company ST Xiangxue has received clinical trial approvals for its drug TAEST16001 targeting advanced esophageal cancer and advanced non-small cell lung cancer, but has not yet initiated Phase II clinical trials [2]. Group 1: Clinical Progress - TAEST16001 has obtained clinical trial approvals for both advanced esophageal cancer (2024LP02791) and advanced non-small cell lung cancer (2025LP00282) [2]. - As of now, the company has not started the clinical trials for these indications [2]. - Future research and development progress will be disclosed in accordance with information disclosure rules and actual circumstances [2].